In der ASCO Developmental Therapeutics – Immunotherapy Session präsentiert Dr. Howard Safran ermutigende Daten zur Phase 1/2-Studie von Dragonflys DF1001, einem immunologischen TriNKET®, das auf HER2 bei Patienten mit fortgeschrittenen soliden Tumoren abzielt. WALTHAM, Mass., 5. Juni 2023…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.